• Quang Van Ta


Matrix metalloproteinases (MMPs) has collagenase and gelatinase activities. They play important role in cancer invasion and metastasis. There are many MMP inhibitors have been discovered. However, the present inhibitors show adverse effects. Therefore, inhibition of specific types of MMPs has become an attractive target for therapeutic intervention.


Baker, A.H., Edward, D.R, Murphy, G. (2002). Metalloproteinase inhibitors: biological actions and therapeutic apportunities. J Cell Sci. 115: 3719-3227.

Benbow, U., Brinckerhoff, C. E. (1997). The AP-1 site and MMP gene regulation: What isall the fuss about?. Matrix Biology 15: 519-526.

Egeblad, M., Werb, Z. (2002). New functions for the matrix metalloproteinase in cancer progression. Nat. Rev. Cancer 2: 161-174

Itoh, T., Tanioka, M., Yoshida, H., Yoshioka, T., Nishimoto, H. and Itohara, S. (1998). Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Research 58, 1048–1051.

Johanne,M.P., Welsch, D.J., Pelletier, J.P. (2001). Metalloproteinases and inhibitors in arthritic diseases. Best Pract Res Clin Rheumatol 15: 805-829.

Karin, M., Liu, Z.G., Zandi, E. (1997). AP-1 function and regulation. Curr. Opin. Cell Biol. 9:240-246.

Klein, G., Vellenga, E., M.W. Fraaije, Kamps, W.A., De Bont, E.S.J.M. (2004). The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukamia. Crit Rev Oncol Hematol 50: 87-100.

Liotta, L.A., Paweletz, C.P. (2001). Invasion and metastasis.The cancer handbook, Nature publishing group p225-234.

Mook, O. R.F., Frederiks, W. M., Van Noorden, C. J.F. (2004). The role of gelatinase in colorectal cancer progression and metastasis. Biochimi Biophys Acta 1705, 69-89.

Nelson, A.R., Fingleton, B., Rotherberg, M.L. and Matrisian, L.M. (2000) Matrix metalloproteinases: biological activity and clinical implications. J. Clin Oncol 18, 1135–1149.

Overall, C.M., López-Otín, C. (2002). Strategies for MMP inhibition in cancer: inovations for the post trial era. Nat Rev Cancer 2: 657-672

Risto, A.A, Kahari, V.M. (2005). Collagenase in cancer. Biochimie 87: 273-286.

Springman, E.B., Angleton, E.L., Birkedal-Hansen, H., Van Wart, H.E., 1990. Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. Proc Natl Acad Sci U S A. 87:364-368

Sternlicht, M.D., Werb, Z. (2001). How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17:463-516.

Van Wart, H.E., Birkedal-Hansen, H. (1990). The cysteine switch: A principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Nalt. Acad. Sci. 87:5578-5582.

Zhang, L., Shi, J., Feng, J., Klocker, H., Lee, C., Zhang, J. (2004). Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer and Prostatic Diseases 7: 327-332




How to Cite

Ta, Q. V. (2019). MATRIX METALLOPROTEINASE: AN OVERVIEW. TTU Review, 1(5). Retrieved from